How much funding has Neogene Therapeutics raised?

Neogene Therapeutics has raised $125.0M in total funding, most recently a Series A round.

Who are Neogene Therapeutics's investors?

Neogene Therapeutics's investors include AstraZeneca, EcoR1 Capital, Jeito Capital, Syncona Partners, TPG (Growth/Rise), Polaris Partners.

When was Neogene Therapeutics founded?

Neogene Therapeutics was founded in 2018.

Where is Neogene Therapeutics headquartered?

Neogene Therapeutics is headquartered in Amsterdam, Netherlands.

What industry is Neogene Therapeutics in?

Neogene Therapeutics operates in Biotech, Healthcare.

How many employees does Neogene Therapeutics have?

Neogene Therapeutics has 51-200 employees.

Neogene Therapeutics

Acquired

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers

Amsterdam, Netherlands · Founded 2018 · $125.0M raised

Biotech

Healthcare

Headquarters: Amsterdam
Employees: 51–200
Founded: 2018
Business Model: B2B

Website: neogene.com
Total Funding: $125.0M
Last Round: $110.0M Series ASep 2020
Rounds: 2

About

Neogene Therapeutics is a global clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Amsterdam and Santa Monica, Neogene aims to change the treatment paradigm for solid tumors. Acquired by AstraZeneca in January 2023, it operates as a wholly owned subsidiary.

Summary

Neogene Therapeutics is a Biotech company based in Amsterdam, Netherlands, founded in 2018. It has raised $125.0M in total across 2 rounds, most recently a $110.0M Series A round in Sep 2020. Investors include AstraZeneca, EcoR1 Capital and Jeito Capital.